Compare INFU & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INFU | TNXP |
|---|---|---|
| Founded | 2005 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 196.1M | 198.6M |
| IPO Year | 2005 | 2008 |
| Metric | INFU | TNXP |
|---|---|---|
| Price | $10.30 | $12.59 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $15.00 | N/A |
| AVG Volume (30 Days) | 79.8K | ★ 440.8K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 181.82 | 91.75 |
| EPS | ★ 0.31 | N/A |
| Revenue | ★ $143,436,000.00 | $13,107,000.00 |
| Revenue This Year | $3.20 | $558.11 |
| Revenue Next Year | $7.31 | $38.29 |
| P/E Ratio | $33.03 | ★ N/A |
| Revenue Growth | 6.36 | ★ 29.85 |
| 52 Week Low | $4.66 | $11.60 |
| 52 Week High | $11.04 | $69.65 |
| Indicator | INFU | TNXP |
|---|---|---|
| Relative Strength Index (RSI) | 59.47 | 41.70 |
| Support Level | $8.52 | $11.90 |
| Resistance Level | $10.84 | $14.52 |
| Average True Range (ATR) | 0.36 | 0.84 |
| MACD | 0.03 | -0.05 |
| Stochastic Oscillator | 63.25 | 17.60 |
InfuSystems Holdings Inc is a health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. The company's services are provided under two-reportable segments: Patient Services and Device Solutions. Maximum revenue is generated from its Patient Services segment, which provides Durable Medical Equipment (DME) and treatment consumables, handles order and delivery logistics, provides 24/7 nursing support relating to the provided equipment, assumes responsibility for third-party payer Durable Medical Equipment billing, and handles biomedical services for the Durable Medical Equipment. The Device Solutions segment includes equipment rental and sales, consumable sales, and biomedical support services.
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.